Today is September 19, 2018. All times in Eastern Daylight Time.
Ironwood Pharmaceuticals Announces FDA Fast Track Designation for Praliciguat for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals announced that the FDA has granted Fast Track Designation for praliciguat for heart failure with preserved ejection fraction.
Ironwood Pharmaceuticals to Present at Upcoming September Investor ConferencesCAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present corporate updates at two upcoming investor conferences in September: 2018 Wells Fargo Healthcare Confer...
Approval of Linzess® Tablets 0.25 mg in Japan for Additional Indication of Chronic ConstipationTOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Astellas and Ironwood announce that approval has been obtained in Japan for LINZESS for the additional indication of chronic constipation.